The decision comes after a thorough review of Bharat Biotech’s submitted data from clinical trials in the 2-18 years age group for COVAXIN (BBV152) to Central Drugs Standard Control Organisation (CDSCO)
from Top Health News | Latest Health & Healthcare Industry Information and Updates: ET HealthWorld : ETHealthworld.com https://ift.tt/30iTnSm
Home »
Top Health News | Latest Health & Healthcare Industry Information and Updates: ET HealthWorld : ETHealthworld.com
» Bharat Biotech's Covaxin gets SEC nod for use in children aged 2-18 years
https://ift.tt/eA8V8J
No comments:
Post a Comment